Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02359851
Title Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Indications

uveal melanoma

Therapies

Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.